International Society of Gynecological Pathologists Symposium 2007

Similar documents
Bibliography. Serous Tumors of the Ovary. Nomenclature

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Low-Grade Serous Ovarian Tumors Debra A. Bell, MD Mayo Clinic and Mayo Medical School Rochester, MN

Introduction. Agenda. Pathogenesis. Pathogenesis and Clinical Implications. Pathogenesis and Clinical Implications

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Mucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology

Ovarian carcinoma classification. Robert A. Soslow, MD

Low-grade serous neoplasia. Robert A. Soslow, MD

Borderline tumors. Borderline tumors. Serous borderline tumor are NOT benign. Low grade serous carcinoma: pathogenesis. Serous carcinoma: pathogenesis

Atypical Hyperplasia/EIN

Case # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor

Serous Borderline Tumors of the Ovary: Implants, Manifestations, Biology & New Insights in Progression

Invited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology

A Survay on Appendiceal Involvement in Ovarian Mucinous Tumors

Endometrial Metaplasia, Hyperplasia & Other Cancer Mimics: a Consultant s Experience

of 20 to 80 and subsequently declines [2].

Section 1. Biology of gynaecological cancers: our current understanding

SEROUS TUMORS. Dr. Jaime Prat. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona

Borderline Ovarian Mucinous Tumors: Consensus Points and Persistent Controversies Regarding Nomenclature, Diagnostic Criteria, and Behavior

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

Mucinous Adenocarcinoma Involving the Ovary: Comparative Evaluation of the Classification Algorithms using Tumor Size and Laterality

Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran

Ovarian Clear Cell Carcinoma

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

Case Report Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors

JMSCR Vol 05 Issue 11 Page November 2017

GOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles

GOBLET CELL CARCINOID

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Case Report Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

Gynecologic Cytopathology: Glandular lesions

Follicular Derived Thyroid Tumors

The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland

Clinical History USCAP Specialty Conference. Gynecologic Pathology Case 3

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)

Papillary Lesions of the Breast: WHO Update

USCAP 2013: THE ORIGINS OF OVARIAN CANCER: MUCINOUS TUMORS

Romanian Journal of Morphology and Embryology 2006, 47(1):53 58

6/5/2010. Outline of Talk. Endometrial Alterations That Mimic Cancer & Vice Versa: Metaplastic / reactive changes. Problems in Biopsies/Curettages

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case 4 Diagnosis 2/21/2011 TGB

Original contribution

Mousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat

05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

Dr Agata T Kochman Wishaw General Hospital

Unknown Slides Conference

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:

64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus

Histological Typing Of Cancer And Precancer Of The Oral Mucosa

Endometrial hyperplasia vs. Intraepithelial neoplasia. Martin Chang, MD PhD FRCPC Pathology Update Friday November 9, 2012

Important Recent Advances in Gynaecological Pathology

3 cell types in the normal ovary

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

Dr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Select problems in cystic pancreatic lesions

Ovarian serous tumors of low malignant potential

When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?

Villoglandular adenocarcinoma of cervix a tumour with bland cytological features: report of a case missed on cytology

Presenter: Yeh-Han Wang M.D.

Spectrum of Lesions in Cystoscopic Bladder Biopsies -A Histopathological Study

Neoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath

The Origin of Pelvic Low-Grade Serous Proliferative Lesions

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Neuroendocrine Lung Tumors Myers

Salivary Glands 3/7/2017

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Pathobiology of ovarian carcinomas

Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study

Demystifying Endometrial Hyperplasia

ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS

Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma

Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz

GOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles

THYMIC CARCINOMAS AN UPDATE

5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.

Outline 11/2/2017. Pancreatic EUS-FNA general aspects. Cytomorphologic features of solid neoplasms/lesions of the pancreas

Neoplasias Quisticas del Páncreas

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

BOSNIAN-TURKISH CYTOPATHOLOGY SCHOOL June 18-19, 2016 Sarajevo. Case Discussions. 60 year old woman Routine gynecologic control LBC

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Morphological effects of chemotherapy on ovarian carcinoma

Division of Pathology

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy

Int. J. Curr. Res. Med. Sci. (2017). 3(1): International Journal of Current Research in Medical Sciences

Endometrial Hyperplasia: A Clinicopathological Study in a Tertiary Care Hospital

Syllabus. Appendiceal GCC and LAMN Navigating the Alphabet Soup in the Appendix. Appendiceal tumors. Summary provided Complete presentation

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Biliary tract tumors

David Nunns on behalf of the Gynae Guidelines Group Date:

ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.

G3.02 The malignant potential of the neoplasm should be recorded. CG3.02a

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY

Disclosure. Case. Mixed Tumors of the Uterine Corpus and Cervix. I have nothing to disclose

Note: The cause of testicular neoplasms remains unknown

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Transcription:

International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade has been found to be an important prognostic factor in cases of ovarian carcinoma o However, there is no system that is universally used for grading these neoplasms At present, it seems that ovarian cancer represents a heterogeneous group of diseases o Different histologic parameters may needed to determine the biological behavior of different tumors Serous Carcinoma Based on the cytologic atypia (primary parameter) and mitotic index (secondary parameter) o Two types High grade (marked variation [ 3:1] in nuclear size and shape with irregular chromatin and variable presence of macronucleoli, and a mitotic index >12 mitoses per 10 high power fields) Low grade (uniform round or oval nuclei with evenly distributed chromatin and variable

presence of nucleoli and a mitotic index of up 12 mitoses per 10 high power fields) Endometrioid Carcinoma Based on the amount of solid component o Three grades Grade 1, up to 5% solid component (nonmorular) Grade 2, >5 to 50% solid component (nonmorular) Grade 3, more than 50% solid component (non-morular) Mucinous Carcinoma Based on the presence and type of invasion o Two types Non-invasive (intraglandular) Invasive Expansile Infiltrative Clear Cell Carcinoma High grade carcinoma Transitional Cell Carcinoma High grade carcinoma Undifferentiated Carcinoma High grade carcinoma

Bibliography 1. Lee KR and Scully RE. Mucinous tumors of the ovary. A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with pseudomyxoma peritonei. Am J Surg Pathol 2000; 24: 1447-1464. 2. Lee KR, Tavassoli FA, Prat J, et al. Surface epithelialstromal tumors, Tumors of the Ovary and Peritoneum. In: WHO Classification of Tumors, Pathology and Genetics, Tumors of the Breast and Female Genital Organs. Eds. Tavassoli, FA and Devilee, P. IARCPress Lyon, Washington, D.C., USA, 2003; pp. 117-161. 3. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28: 496-504. 4. Malpica, et al. Inter-observer and intra-observer variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007 (in press). 5. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinaltype mucinous tumors. Atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999; 23: 617-635. 6. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. Cancer. 1989; 63: 839-847. 7. Silva, EG, Robey-Cafferty, SS, Smith TL, Gershenson, DM. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol. 1990; 93: 457-465. 8. Silva EG and Gershenson DM. Standardized histologic grading of epithelial ovarian cancer: Elusive after all

these years. (Editorial) Gynecologic Oncology. 1998; 70:1. 9. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih l-m. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002; 160: 1223-1228. 10. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004; 23: 200-205.

International Society of Gynecological Pathologists Symposium 2007 Grading of Ovarian Cancer Anaís Malpica, M.D. Department of Pathology

Grading of Ovarian Cancer Introduction Traditionally ovarian cancer has been considered one disease Diverse grading systems have been used to grade these neoplasms regardless of the tumor histotype

Grading of Ovarian Cancer The FIGO grading system Based on architectural features, grade of the tumor depends on the ratio of glandular or papillary structures to solid tumor Grade 1, < 5% solid Grade 2, 5% to 50% solid Grade 3, >50% solid

Grading of Ovarian Cancer The WHO system Based on the pathologist s impression of both architectural and cytologic features Categories not defined according to a quantitative method

Grading of Ovarian Cancer Ovarian carcinoma appears to be a heterogeneous group of tumors, rather than a single disease Therefore, a universal grading system for this heterogeneous group most likely would not accommodate the inherent differences among these diverse tumors

Grading of Ovarian Cancer Considering this heterogeneity, it would be more appropriate to use different parameters in order to grade the cases within each histologic type

Grading of Ovarian Cancer Serous Carcinoma The recently proposed two-tier grading system (M.D. Anderson grading system) has emerged as a good method to segregate serous carcinomas that have different molecular, pathogenetic, histologic, immunohistochemical, and clinical features

Serous Carcinoma The two-tier grading system (M.D. Anderson grading system) is based primarily on the assessment of nuclear atypia with the mitotic rate used as a secondary feature Two grades: Low High

Low Grade Serous Carcinoma Definition A serous carcinoma characterized by the presence of uniform cells with mild to moderate nuclear atypia, and usually a low mitotic index ( 12 mitoses per 10 HPFs)

High Grade Serous Carcinoma Definition A serous carcinoma characterized by the presence of pleomorphic cells with marked nuclear atypia ( 3:1 variation in size and shape), and a high mitotic index (>12 mitoses per 10 HPFs)

Low vs. High Grade Serous Carcinoma Differences in Pathogenesis: Morphologic Evidence Association with a serous neoplasm of low malignant potential 60% of the low grade serous carcinomas 2% of the high grade serous carcinomas Malpica A et al, 2004

Low vs. High Grade Serous Carcinoma Differences in Pathogenesis: Morphologic Evidence Association with serous tumor of low malignant potential 276 pts with serous LMP and long-term ( 5-year) f/u Transformation to low grade serous carcinoma in 6.8% of pts Interval range, 7 to 288 months (58% 60 months) Longacre TA et al, 2005

Low vs. High Grade Serous Carcinoma Differences in Pathogenesis: Molecular Evidence Ovarian Tumorigenesis Model Type I, tumors that arise in a stepwise manner from borderline (low malignant potential) tumors Low grade serous carcinoma, prototypic type I tumor BRAF and KRAS mutations Singer G et al, 2002

Low vs. High Grade Serous Carcinoma Differences in Pathogenesis: Molecular Evidence Ovarian Tumorigenesis Model Type II, de novo development (as yet no recognizable precursor lesion identified) High grade serous carcinoma, prototypic type II tumor p53 mutation Singer G et al, 2002

Low vs. High Grade Serous Carcinoma: Immunohistochemical Differences Antibody Low Grade Serous Ca High Grade Serous Ca p53 Bcl-2 MIB1, mean index Her-2 neu C-Kit 18% 5% 23.0% 4.5% 4.5% 64% 26% 55.4% 36% 30% O Neill CJ et al, 2005

Low vs. High Grade Serous Carcinoma: Differences in Biologic Behavior Low grade serous carcinoma appears to be less responsive to conventional chemotherapy than high grade serous carcinoma Patients with low grade serous carcinoma have a longer overall survival than patients with high grade serous carcinoma Gershenson DM, et al, 2006

Low vs. High Grade Serous Carcinoma: Frequently Asked Questions What is the incidence of low grade serous carcinoma? Uncommon tumor Less than 10% of ovarian serous carcinomas (MDACC unpublished data) 1/102 cases of advanced stage ovarian cancer (Gilks CB, 2004) Is the term low grade serous carcinoma used in a standard fashion? No Some gynecological pathologists use this term to designate the micropapillary/cribriform variant of a serous tumor of low malignant potential

Low vs. High Grade Serous Carcinoma: Frequently Asked Questions What is the reproducibility of the two-tier grading system for ovarian serous carcinoma? Overall kappa among 9 different observers = 0.909 The inter-observer kappas ranged from 0.717 to 1.000 in the first round of the review and from 0.701 to 1.000 in the second review Malpica A et al, in press 2007

Low vs. High Grade Serous Carcinoma: Frequently Asked Questions What is the reproducibility of the two-tier grading system for ovarian serous carcinoma? Eight of 9 participants had an intra-grader kappa ranging from 0.775 to 1.000 (excellent agreement) One participant had an intra-grader kappa of 0.725 (good agreement) Malpica A et al, in press 2007

Endometrioid Carcinoma Grading system similar to the FIGO grading system used for endometrial endometrioid adenocarcinoma

Endometrioid Carcinoma Grade 1 : less than 5% solid areas

Endometrioid Carcinoma Grade 2 : 5 to 50% solid areas

Endometrioid Carcinoma Grade 3 : more than 50% solid areas

Endometrioid Carcinoma Survival rate of patients with grade 1 or 2 tumors is higher than those with grade 3 tumors Kline RC et al, 1990

Clear Cell Carcinoma By definition a high grade carcinoma The WHO recommendation is not to grade

Clear Cell Carcinoma

Clear Cell Carcinoma A high incidence of stage I disease Poor response to platinum-based therapy Controversial results regarding the survival of patients with this type of tumor when compared to patients with serous carcinoma

Transitional Cell Carcinoma The WHO recommendation is to grade according to the criteria used for transitional cell carcinoma of the urinary tract In reality, most (if not all) cases are high grade

Transitional Cell Carcinoma WHO criteria Low grade Uniformly enlarged nuclei, with mild alteration of the polarity and mild differences in shape, contour, and chromatin distribution Infrequent mitoses High grade Marked variation in nuclear polarity, size, shape, and chromatin distribution Frequent mitoses

Transitional Cell Carcinoma Ovarian carcinomas with more than 50% of a TCC component appear to have a better response to chemotherapy Especially if the TCC component is also predominant in the metastases

Mucinous Carcinoma Non-invasive carcinoma (Intraepithelial) Marked atypia of the epithelium Invasive carcinoma Expansile or confluent type Confluent glandular pattern uninterrupted by normal ovarian stroma occupying an area measuring more than 5 mm in diameter (The Johns Hopkins group criterion) or more than 10 mm 2 (WHO criterion) Infiltrative type Small glands, nest of cells or individual cells infiltrating the stroma in an area measuring more than 5 mm in diameter (The Johns Hopkins group criterion) or more than 10 mm 2 (WHO criterion)

Mucinous Carcinoma Prognosis Intraepithelial mucinous carcinoma Risk of recurrence for stage I cases: 5.8% Invasive carcinoma 5-year survival of 91% for stage I cases; advanced stage cases all died of disease (Riopel MA et al, 1999) Infiltrative stromal invasion appears to be more aggressive than expansile invasion (Lee KR and Scully RE, 2000 and Rodriguez IM and Prat J, 2002)

Undifferentiated Carcinoma By definition a high grade carcinoma The 5-year survival of patients with undifferentiated carcinoma is worse than that of patients with serous carcinoma or transitional cell carcinoma

Grading of Ovarian Cancer Summary Serous Carcinoma Categories: High grade Low grade Criteria: Degree of cytologic atypia (primary feature) and mitotic index (secondary feature) Endometrioid Carcinoma Categories: Grades 1, 2, and 3 Criterion: amount of solid component

Grading of Ovarian Cancer Summary Mucinous Carcinoma Categories: Non-invasive (intraepithelial) Invasive Expansile or confluent vs. infiltrative Criteria: Marked cytologic atypia (non-invasive carcinoma)

Grading of Ovarian Cancer Summary Mucinous Carcinoma Criteria: Invasion Glandular crowding without intervening ovarian stroma in an area measuring more than 5 mm in diameter (confluent or expansile pattern) Small glands, clusters of cells or individual cells in the stroma in an area measuring more than 5 mm in diameter (infiltrative pattern)

Grading of Ovarian Cancer Summary Transitional cell carcinoma Categories: Almost always high grade Criteria: WHO criteria for urothelial carcinoma High grade carcinomas (by definition) Clear cell carcinoma Undifferentiated carcinoma